Novel C-nucleosides of tiazofurin analogue (2-[2-(hydroxymethyl)-1, 3-dioxolan-5-yl]1, 3-thiazole-4-carboxamide) and its thiol-substituted derivative (2-[2-(mercaptomethyl)-1,3-dioxolan -5-yl]1, 3-thiazole-4-carboxami...Novel C-nucleosides of tiazofurin analogue (2-[2-(hydroxymethyl)-1, 3-dioxolan-5-yl]1, 3-thiazole-4-carboxamide) and its thiol-substituted derivative (2-[2-(mercaptomethyl)-1,3-dioxolan -5-yl]1, 3-thiazole-4-carboxamide) were synthesized from methyl acrylate through a multistep procedure. Their structures were confirmed by IR, 1HNMR, 13CNMR and elemental analysis.展开更多
To the Editor:Respiratory syncytial virus(RSV)is a major cause of acute lower respiratory tract infections worldwide,posing a significant threat to infants,young children,immunocompromised individuals,and the elderly1...To the Editor:Respiratory syncytial virus(RSV)is a major cause of acute lower respiratory tract infections worldwide,posing a significant threat to infants,young children,immunocompromised individuals,and the elderly1.Nearly all children are infected by the age of two,with about half experiencing multiple infections.In 2019,RSV was responsible for approximately 33 million lower respiratory tract infections in children under five,resulting in 3.6 million hospitalizations and over 100,000 deaths2.In older adults,the incidence of RSV reaches 600.7 cases per 100,000 individuals in developed countries,with mortality rates as high as 9.1%in developing regions.Collectively,the global disease burden of RSV has become comparable to that of seasonal influenza.展开更多
文摘Novel C-nucleosides of tiazofurin analogue (2-[2-(hydroxymethyl)-1, 3-dioxolan-5-yl]1, 3-thiazole-4-carboxamide) and its thiol-substituted derivative (2-[2-(mercaptomethyl)-1,3-dioxolan -5-yl]1, 3-thiazole-4-carboxamide) were synthesized from methyl acrylate through a multistep procedure. Their structures were confirmed by IR, 1HNMR, 13CNMR and elemental analysis.
基金supported by National Key R&D Program of China(2021YFA1500201)National Natural Science Foundation of China(82404430)+4 种基金High Level of Special Funds(G03050K003,China)Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis(ZDSYS20190902093215877,China)Shenzhen Science and Technology Program(JCYJ20220530113609021,China)Project of Guangzhou National Laboratory(GZNL2023A01008,China)Shenzhen High-tech Development Special Plan Pingshan District Innovation Platform Project(29853M-KCJ-2023-068-01,China).
文摘To the Editor:Respiratory syncytial virus(RSV)is a major cause of acute lower respiratory tract infections worldwide,posing a significant threat to infants,young children,immunocompromised individuals,and the elderly1.Nearly all children are infected by the age of two,with about half experiencing multiple infections.In 2019,RSV was responsible for approximately 33 million lower respiratory tract infections in children under five,resulting in 3.6 million hospitalizations and over 100,000 deaths2.In older adults,the incidence of RSV reaches 600.7 cases per 100,000 individuals in developed countries,with mortality rates as high as 9.1%in developing regions.Collectively,the global disease burden of RSV has become comparable to that of seasonal influenza.
